Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension; a pilot efficacy trial

Circulation Journal

Volumn 77, Issue 10, 2013, Pages 2619-2625

  Fukumoto, Yoshihiro ^a   Yamada, Norikazu ^b   Matsubara, Hiromi ^c   Mizoguchi, Minori ^d   Uchino, Kazuaki ^e   Yao, Atsushi ^f   Kihara, Yasuki ^g   Kawano, Mitsuhiro ^h   Watanabe, Hiroshi ⁱ   Takeda, Yutaka ^j   Adachi, Takeshi ^k   Osanai, Shinobu ^l   Tanabe, Nobuhiro ^m   Inoue, Teruo ⁿ   Kubo, Akihiro ^o   Ota, Yuri ^o   Fukuda, Koichiro ^o   Nakano, Takeshi ^p   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^f UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^g HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^h KANAZAWA UNIVERSITY   (Japan)

ⁱ HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^k NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^l ASAHIKAWA MEDICAL COLLEGE   (Japan)

^m CHIBA UNIVERSITY   (Japan)

ⁿ DOKKYO MEDICAL UNIVERSITY   (Japan)

^o ASAHI KASEI PHARMA CORPORATION   (Japan)

^p Kuwana East Medical Center   (Japan)

more..

Author keywords

Pulmonary arterial hypertension; Rho kinase inhibitor; Signal transduction

Indexed keywords

FASUDIL; HYDROXYFASUDIL; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART INDEX; HUMAN; KIDNEY DISEASE; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG HEMODYNAMICS; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PLEURA EFFUSION; PROTEINURIA; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIC PURPURA; UREA NITROGEN BLOOD LEVEL; WALKING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES;

EID: 84884603855     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0443     Document Type: Article

References (32)

1. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55-S66.
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classifcation of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
3. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
4. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S-24S.
5. Miura Y, Fukumoto Y, Sugimura K, Oikawa M, Nakano M, Tatebe S, et al. Identifcation of new prognostic factors of pulmonary hypertension. Circ J 2010; 74: 1965-1971.
6. Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J 2011; 75: 1801-1810.
7. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431.
8. Satoh T, Saji T, Watanabe H, Ogawa S, Takehara K, Tanabe N, et al. A phase III, multicenter, collaborative, open-label clinical trial of sildenafl in Japanese patients with pulmonary arterial hypertension. Circ J 2011; 75: 677-682.
9. Yanagisawa R, Kataoka M, Taguchi H, Kawakami T, Tamura Y, Fukuda K, et al. Impact of first-line sildenafl monotreatment for pulmonary arterial hypertension. Circ J 2012; 76: 1245-1252.
10. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 1995; 270: 29051-29054.
11. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996; 15: 1885-1893.
12. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997; 275: 1308-1311.
13. Narumiya S. The small GTPase Rho: Cellular functions and signal transduction. J Biochem 1996; 120: 215-228.
14. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
15. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-334.
16. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2002; 39: 319-327.
17. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94: 385-393.
18. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91: 391-392.
19. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, et al. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol 2006; 48: 280-285.
20. Do e Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 2009; 73: 1731-1739.
21. Machado RD, James V, Southwood M, Harrison RE, Atkinson C, Stewart S, et al. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 2005; 111: 607-613.
22. Dorfmuller P, Perros F, Balabanian K, Humbert M. Infammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
23. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, et al. Infammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 2004; 37: 537-546.
24. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardio-vasc Pharmacol 2007; 50: 17-24.
25. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-asso-ciated protein kinase in hypertension. Nature 1997; 389: 990-994.
26. Oka M, Fagan KA, Jones PL, McMurtry IF. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008; 155: 444-454.
27. Abe K, Morikawa K, Hizume T, Uwatoku T, Oi K, Seto M, et al. Prostacyclin does not inhibit Rho-kinase: An implication for the treatment of pulmonary hypertension. J Cardiovasc Pharmacol 2005; 45: 120-124.
28. Tawara S, Fukumoto Y, Shimokawa H. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-in-duced pulmonary hypertension in rats. J Cardiovasc Pharmacol 2007; 50: 195-200.
29. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, et al. Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70: 174-178.
30. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
31. Shimokawa H, Rashid M. Rho-kinase inhibitors for cardiovascular medicine: Its rationale and current status. Trends Pharmacol Sci 2007; 28: 296-302.
32. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010; 25: 144-149.